133 related articles for article (PubMed ID: 38430625)
41. Diabetes and prediabetes in children with cystic fibrosis.
Schiaffini R; Pampanini V
Curr Opin Pediatr; 2023 Aug; 35(4):481-485. PubMed ID: 37211992
[TBL] [Abstract][Full Text] [Related]
42. The effect of probiotic administration on metabolomics and glucose metabolism in CF patients.
Gur M; Zuckerman-Levin N; Masarweh K; Hanna M; Laghi L; Marazzato M; Levanon S; Hakim F; Bar-Yoseph R; Wilschanski M; Bentur L
Pediatr Pulmonol; 2022 Oct; 57(10):2335-2343. PubMed ID: 35676769
[TBL] [Abstract][Full Text] [Related]
43. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.
Darukhanavala A; Van Dessel F; Ho J; Hansen M; Kremer T; Alfego D
PLoS One; 2021; 16(4):e0250036. PubMed ID: 33882078
[TBL] [Abstract][Full Text] [Related]
44. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.
Potter KJ; Racine F; Bonhoure A; Boudreau V; Bélanger N; Coriati A; Shohoudi A; Lavoie A; Senior PA; Mailhot G; Rabasa-Lhoret R
Diabetes Metab; 2023 Jul; 49(4):101455. PubMed ID: 37271306
[TBL] [Abstract][Full Text] [Related]
45. The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis.
Ripa P; Robertson I; Cowley D; Harris M; Masters IB; Cotterill AM
Clin Endocrinol (Oxf); 2002 Mar; 56(3):383-9. PubMed ID: 11940051
[TBL] [Abstract][Full Text] [Related]
46. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis.
Franzese A; Valerio G; Buono P; Spagnuolo MI; Sepe A; Mozzillo E; De Simone I; Raia V
J Pediatr Endocrinol Metab; 2008 Feb; 21(2):109-16. PubMed ID: 18422023
[TBL] [Abstract][Full Text] [Related]
47. Advances in cystic fibrosis-related diabetes: Current status and future directions.
Lurquin F; Buysschaert M; Preumont V
Diabetes Metab Syndr; 2023 Nov; 17(11):102899. PubMed ID: 37939435
[TBL] [Abstract][Full Text] [Related]
48. Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET).
Coriati A; Ziai S; Azar M; Berthiaume Y; Rabasa-Lhoret R
J Cyst Fibros; 2016 Jan; 15(1):127-32. PubMed ID: 25818059
[TBL] [Abstract][Full Text] [Related]
49. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.
Tofé S; Moreno JC; Máiz L; Alonso M; Escobar H; Barrio R
Eur J Endocrinol; 2005 Feb; 152(2):241-7. PubMed ID: 15745932
[TBL] [Abstract][Full Text] [Related]
50. Novel time-saving OGTT sparing HbA1c-HOMA2 based algorithm for the diagnosis of cystic fibrosis-related diabetes.
Lurquin F; Gohy S; Hermans MP; Preumont V
Diabetes Res Clin Pract; 2024 Feb; 208():111124. PubMed ID: 38309533
[TBL] [Abstract][Full Text] [Related]
51. Continuous glucose monitoring indices predict poor FEV
Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
[TBL] [Abstract][Full Text] [Related]
52. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis.
Weiss L; Reix P; Mosnier-Pudar H; Ronsin O; Beltrand J; Reynaud Q; Mely L; Burgel PR; Stremler N; Rakotoarisoa L; Galderisi A; Perge K; Bendelac N; Abely M; Kessler L
Diabetes Metab; 2023 May; 49(3):101444. PubMed ID: 37030530
[TBL] [Abstract][Full Text] [Related]
53. Relationship between exercise capacity and glucose tolerance in cystic fibrosis.
Foster K; Huang G; Zhang N; Crisalli J; Chini B; Amin R; Elder D
Pediatr Pulmonol; 2018 Feb; 53(2):154-161. PubMed ID: 29115018
[TBL] [Abstract][Full Text] [Related]
54. Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes.
Potter KJ; Boudreau V; Bonhoure A; Tremblay F; Lavoie A; Carricart M; Senior PA; Rabasa-Lhoret R
J Cyst Fibros; 2023 Jan; 22(1):50-58. PubMed ID: 36028423
[TBL] [Abstract][Full Text] [Related]
55. HbA1c as a screening tool for cystic fibrosis related diabetes.
Burgess JC; Bridges N; Banya W; Gyi KM; Hodson ME; Bilton D; Simmonds NJ
J Cyst Fibros; 2016 Mar; 15(2):251-7. PubMed ID: 25869326
[TBL] [Abstract][Full Text] [Related]
56. Glycated Hemoglobin as a First-line Screening Test for Cystic Fibrosis‒Related Diabetes and Impaired Glucose Tolerance in Children With Cystic Fibrosis: A Validation Study.
Racine F; Shohoudi A; Boudreau V; Nguyen CQT; Denis MH; Desjardins K; Reynaud Q; Rabasa-Lhoret R; Mailhot G
Can J Diabetes; 2021 Dec; 45(8):768-774. PubMed ID: 33926819
[TBL] [Abstract][Full Text] [Related]
57. A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers.
Hicks R; Ode KL; Vigers T; Chan CL
Front Endocrinol (Lausanne); 2023; 14():1183288. PubMed ID: 37274323
[TBL] [Abstract][Full Text] [Related]
58. Abnormal glucose tolerance in a pediatric cystic fibrosis cohort: Trends in clinical outcomes and associated factors in the preceding years.
Nguyen CQT; Denis MH; Chagnon M; Rabasa-Lhoret R; Mailhot G
Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):277-285. PubMed ID: 32981797
[TBL] [Abstract][Full Text] [Related]
59. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study.
O'Riordan SM; Hindmarsh P; Hill NR; Matthews DR; George S; Greally P; Canny G; Slattery D; Murphy N; Roche E; Costigan C; Hoey H
Diabetes Care; 2009 Jun; 32(6):1020-2. PubMed ID: 19279304
[TBL] [Abstract][Full Text] [Related]
60. Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Misgault B; Chatron E; Reynaud Q; Touzet S; Abely M; Melly L; Dominique S; Troussier F; Ronsin-Pradel O; Gerardin M; Mankikian J; Cosson L; Chiron R; Bounyar L; Porzio M; Durieu I; Weiss L; Kessler R; Kessler L
J Cyst Fibros; 2020 Sep; 19(5):712-716. PubMed ID: 32201160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
